85/100 · Critical
Manufactured by Hospira, Inc.
Docetaxel Anhydrous Adverse Events: High Seriousness and Diverse Reactions
152,096 FDA adverse event reports analyzed
Last updated: 2026-05-12
DOCETAXEL ANHYDROUS is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Hospira, Inc.. Based on analysis of 152,096 FDA adverse event reports, DOCETAXEL ANHYDROUS has a safety score of 85 out of 100. This score indicates a relatively favorable safety profile, with fewer or less severe adverse events compared to many other tracked medications. The most commonly reported adverse reactions for DOCETAXEL ANHYDROUS include ALOPECIA, MADAROSIS, HAIR TEXTURE ABNORMAL, HAIR COLOUR CHANGES, HAIR DISORDER. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for DOCETAXEL ANHYDROUS.
Docetaxel Anhydrous has a safety concern score of 85 out of 100, placing it in the high concern category based on analysis of FDA adverse event data. The FDA has received approximately 152,096 adverse event reports for this medication, which is primarily manufactured by Hospira, Inc..
The most commonly reported adverse events include Alopecia, Madarosis, Hair Texture Abnormal. Of classified reports, 77.9% were designated as serious by the FDA, meaning they involved hospitalization, disability, or other significant medical outcomes. Docetaxel anhydrous is associated with a high incidence of serious adverse events, particularly neutropenia and infections.
The drug is linked to a wide range of reactions, including hematological, gastrointestinal, and respiratory issues. Significant psychological and neurological effects, such as anxiety and neuropathy, are also reported.
Patients taking Docetaxel Anhydrous should monitor for the commonly reported side effects and contact their healthcare provider if they experience any unusual symptoms. Docetaxel anhydrous can cause severe hematological and gastrointestinal side effects, and patients should be monitored closely for signs of infection and myelosuppression. Drug interactions, particularly with other cytotoxic agents, should be careful This analysis is based on voluntary FDA adverse event reports and should not replace professional medical advice.
Docetaxel Anhydrous received a safety concern score of 85/100 (high concern). This is based on a 77.9% serious event ratio across 65,204 classified reports. The score accounts for 152,096 total adverse event reports and 100 distinct reaction types. This high score reflects a significant proportion of serious adverse events in the reporting data.
Adverse event reports by sex: Female: 35,926, Male: 15,963, Unknown: 333. The most frequently reported age groups are age 60 (1,344 reports), age 62 (1,336 reports), age 61 (1,332 reports). These demographics reflect reporting patterns and may not represent the full patient population.
Out of 65,204 classified reports for DOCETAXEL ANHYDROUS:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
Docetaxel anhydrous can cause severe hematological and gastrointestinal side effects, and patients should be monitored closely for signs of infection and myelosuppression. Drug interactions, particularly with other cytotoxic agents, should be careful
If you are taking Docetaxel Anhydrous, here are important things to know. The most commonly reported side effects include alopecia, madarosis, hair texture abnormal, hair colour changes, hair disorder. While many of these may be mild and temporary, you should contact your healthcare provider if any symptoms are severe or persistent. Patients should be closely monitored for signs of infection, particularly neutropenia and febrile neutropenia, and treated promptly if detected. Regular blood tests are essential to monitor hematological parameters and adjust treatment as necessary. If you experience a serious adverse reaction, seek emergency medical attention immediately or call 911. You can report side effects to the FDA's MedWatch program at 1-800-FDA-1088.
The FDA continues to monitor the safety of docetaxel anhydrous, and healthcare providers are advised to report any adverse events to the FDA's MedWatch program.
The FDA has received approximately 152,096 adverse event reports associated with Docetaxel Anhydrous. These reports come from healthcare professionals, consumers, and manufacturers through the FDA Adverse Event Reporting System (FAERS). Note that the number of reports does not directly indicate the frequency of side effects, as adverse events are voluntarily reported and may be underrepresented.
The most frequently reported adverse events for Docetaxel Anhydrous include Alopecia, Madarosis, Hair Texture Abnormal, Hair Colour Changes, Hair Disorder. By volume, the top reported reactions are: Alopecia (16,937 reports), Madarosis (6,713 reports), Hair Texture Abnormal (5,993 reports). These figures reflect FDA adverse event reports and may not represent the true incidence rate of these side effects in all patients taking Docetaxel Anhydrous.
Out of 65,204 classified reports, 50,770 (77.9%) were classified as serious and 14,434 as non-serious. The FDA classifies an event as "serious" if it results in death, hospitalization, disability, or other medically significant outcomes. A higher serious-event ratio warrants closer attention but does not necessarily mean the drug is unsafe.
Adverse event reports for Docetaxel Anhydrous break down by patient sex as follows: Female: 35,926, Male: 15,963, Unknown: 333. This distribution reflects reporting patterns rather than actual risk differences between groups. Reporting rates can be influenced by prescribing patterns, disease demographics, and reporting behavior.
The most frequently reported age groups for Docetaxel Anhydrous adverse events are: age 60: 1,344 reports, age 62: 1,336 reports, age 61: 1,332 reports, age 65: 1,326 reports, age 59: 1,287 reports. Age-related reporting patterns can reflect both the demographics of the patient population and potential age-related susceptibility to certain side effects.
The primary manufacturer associated with Docetaxel Anhydrous adverse event reports is Hospira, Inc.. Multiple manufacturers may produce generic versions of this drug. The manufacturer listed reflects the most frequently reported brand in FDA adverse event data.
Beyond the most common reactions, other reported adverse events for Docetaxel Anhydrous include: Diarrhoea, Nausea, Emotional Distress, Anxiety, Neutropenia. Less common side effects can still be clinically significant. Patients should report any unusual symptoms to their healthcare provider.
You can report adverse events from Docetaxel Anhydrous to the FDA through their MedWatch program at www.fda.gov/medwatch, by calling 1-800-FDA-1088, or by completing Form FDA 3500. Healthcare professionals, consumers, and manufacturers can all submit reports. Reporting helps the FDA monitor drug safety after approval.
Docetaxel Anhydrous has a safety concern score of 85 out of 100 (high concern). This score is calculated from the ratio of serious to non-serious adverse events, the diversity of reported reactions, and the overall volume of reports relative to usage. Docetaxel anhydrous is associated with a high incidence of serious adverse events, particularly neutropenia and infections.
Key safety signals identified in Docetaxel Anhydrous's adverse event data include: Neutropenia and febrile neutropenia are the most common serious adverse events.. Alopecia and hair disorders are frequent dermatological reactions.. Neurological effects, including neuropathy and psychological distress, are notable safety signals.. These signals are derived from patterns in FDA reports and should be discussed with a healthcare provider for personalized assessment.
Docetaxel anhydrous can cause severe hematological and gastrointestinal side effects, and patients should be monitored closely for signs of infection and myelosuppression. Drug interactions, particularly with other cytotoxic agents, should be careful Always inform your healthcare provider about all medications, supplements, and over-the-counter drugs you are taking before starting Docetaxel Anhydrous.
Patients should be closely monitored for signs of infection, particularly neutropenia and febrile neutropenia, and treated promptly if detected. Regular blood tests are essential to monitor hematological parameters and adjust treatment as necessary.
Docetaxel Anhydrous has 152,096 adverse event reports on file with the FDA. The drug is linked to a wide range of reactions, including hematological, gastrointestinal, and respiratory issues. The volume of reports for Docetaxel Anhydrous reflects both the drug's usage level and the vigilance of the reporting community.
The FDA continues to monitor the safety of docetaxel anhydrous, and healthcare providers are advised to report any adverse events to the FDA's MedWatch program. For the most current regulatory information, check the FDA's drug labeling database or consult your pharmacist.
Explore other medications manufactured by Hospira, Inc. and compare their safety profiles:
The following drugs share commonly reported adverse reactions with DOCETAXEL ANHYDROUS:
Drugs related to DOCETAXEL ANHYDROUS based on therapeutic use, drug class, or shared indications: